<DOC>
	<DOC>NCT00954356</DOC>
	<brief_summary>The purpose of this trial is to determine if XPF-001 is effective for the treatment of pain following third-molar/wisdom tooth extraction.</brief_summary>
	<brief_title>Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction</brief_title>
	<detailed_description />
	<mesh_term>Toothache</mesh_term>
	<criteria>Males (aged 1860) and females of nonchildbearing potential (aged 1860; BMI between 19.5 to 32.0 kg/m2; Outpatient, scheduled to undergo surgical extraction of 2 or more impacted 3rd molars (with at least 1 partial bony mandibular extraction); use of only the following preoperative medications 2% lidocaine with epinephrine and nitrous oxide; Able to complete the requested information on analgesic questionnaires and able to comply with study procedures and restrictions; Able to read, comprehend and sign the consent form; Deemed medically healthy to participate in the study, with normal or clinically insignificant medical history, physical examination, lab tests and ECG results; No contraindications to the study drug, it excipients or any of the study medications including rescue medications. Presence of a clinically significant medical condition; Positive test for HIV, Hepatitis B or Hepatitis C; Use of any prescription or over the counter medication or supplement in the 48 hours before dose of study drug until discharge; Acute local infection at the time of dental surgery; Females who are pregnant, lactating or of childbearing potential, or who provide a positive pregnancy test result at screening or checkin; Males not undertaking adequate measures to prevent their partner becoming pregnant throughout the study; Clinically significant laboratory values; Clinically significant abnormal ECG; History or presence of alcoholism, or alcohol or substance abuse (within previous 2 years), or routine consumption of 3 or more alcoholic drinks per day; A positive urine drug test; Routine use of analgesics 5 or more times per week; Presence or history (within 2 years of enrolment) of bleeding disorder(s) or peptic ulcer disease; History of allergic reaction to any drug, including penicillin; Ingestion of caffeine containing foods or drinks in the 24 hours before dose of study drug; Consumption of alcohol in the 48 hours before dose of study drug, or a positive alcohol breath test at checkin; Consumption of grapefruit or grapefruit containing products in the 7 days before dose of study drug; Use of tobacco or nicotine substitutes within 1 month of dose of study drug, or inability to refrain from use of nicotine between checkin and follow up; Treatment for depression in the 6 months prior to enrolment; Use of another investigational drug in the 60 days before enrolment; Donation or loss of 50500 mL of blood in the 30 days prior to enrolment, or more than 500 mL of blood in the 56 days before enrolment; Previously entered into this study; Study site or Sponsor employees or relatives of employees directly involved in the study; Any other condition that (in the opinion of the Investigator or sponsor) makes the subject unsuitable for the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Pain following 3rd molar/wisdom tooth extraction</keyword>
</DOC>